Vanzacaftor/tezacaftor/deutivacaftor
Fixed-dose combination for cystic fibrosis, approved in 2024–2025.
Vanzacaftor/tezacaftor/deutivacaftor (Alyftrek) is a fixed-dose combination medication for cystic fibrosis, containing a CFTR potentiator and two other agents. It is taken orally and approved for people aged six and older with at least one F508del or other responsive CFTR mutation. The combination was approved in the United States in December 2024, in the European Union in June 2025, and in Canada in July 2025.
Quick Facts
- Trade name
- Alyftrek
- Routes of administration
- By mouth
Facts from the source article.
More in Cystic Fibrosis
Dorothy Hansine AndersenAtalurenCFTR inhibitory factorCongenital absence of the vas deferensCystic fibrosis transmembrane conductance regulatorCystic fibrosis–related diabetesDistal intestinal obstruction syndromeDornase alfaElexacaftor/tezacaftor/ivacaftorFibrosing colonopathyPeter GrootenhuisImmunoreactive trypsinogen
Spotted an error? Know more?
Reader corrections go straight into our review queue. Suggest an edit · How this site is sourced
Comments
Loading…